A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.
Comprehensive, easy-to-understand information about this condition
How we create this content →Report Generation Failed
We couldn't automatically generate the report. This may be due to temporary service issues.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease
Aduro BioTech, Inc.
Other
Avenge Bio, Inc.
Other
Bayer HealthCare Pharmaceuticals Inc.
Other
Boehringer Ingelheim Pharmaceuticals, Inc.
Other
Bristol-Myers Squibb Company
Other
Eisai Inc.
Other
Epizyme, Inc.
Other
Flag Therapeutics, Inc.
Other
Genentech, Inc.
Other
Ikena Oncology
Other
Insilico Medicine Hong Kong Limited
Other
Kygent Therapeutics (Shanghai) Co., Ltd.
Other
Merck & Co., Inc.
Other
Mirati Therapeutics, Inc
Other
Momotaro-Gene Inc.
Other
Oncovita SAS
Other
PURMX Therapeutics, Inc.
Other
PlumeStars s.r.l.
Other
Polaris Group
Other
RS Oncology, LLC
Other
SELLAS Life Sciences Group, Inc.
Other
Shanghai Cell Therapy Group Pharmaceutical Technology Co., Ltd.
Other
TCR2 Therapeutics, Inc., a wholly owned subsidiary of Adaptimmune Therapeutics plc
Other
TREAT U, S.A.
Other
Ultimovacs ASA
Other
Verastem Inc.
Other
Verismo Therapeutics
Other
Vivace Therapeutics
Other